Samuel Bakhoum, M.D., PH.D.

Chief Scientific Officer

Samuel Bakhoum is a physician-scientist and a leader in the field of chromosomal instability and its role in cancer. As a scientific co-founder and board member of Volastra Therapeutics, he has been instrumental in the company’s mission since its inception. Prior to joining Volastra full-time, Dr. Bakhoum was an Associate Member (Professor) in the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center (MSKCC), where he also served as a practicing radiation oncologist. His research uncovered key insights into how chromosomal instability fuels cancer progression and has authored over 80 scientific publications on the subject. Dr. Bakhoum completed his postdoctoral training with Dr. Lewis Cantley at Weill Cornell Medicine and his radiation oncology training at MSKCC. He earned his M.D. and Ph.D. from Geisel School of Medicine at Dartmouth.